EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation

Andra V Krauze iD, Yingdong Zhao, Ming-Chung Li, Joanna Shih, Will Jiang, Erdal Tasci iD, Theresa Cooley Zgela, Mary Sproull, Megan Mackey, Uma Shankavaram, Philip Tofilon, Kevin Camphausen

Biomolecules · 10.10.2023 · 13 (10) · 1499

DOI: 10.3390/biom13101499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 10.10.2023. Verfasst von Andra V Krauze und 11 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), 9000 Rockville Pike, Building …. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NCI NIH intramural program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is the most common brain tumor with an overall survival (OS) of less than 30% at two years. Valproic acid (VPA) demonstrated survival benefits documented in retrospective and prospective trials, when used in combination with chemo-radiotherapy (CRT).

Purpose

The primary goal of this study was to examine if the differential alteration in proteomic expression pre vs. post-completion of concurrent chemoirradiation (CRT) is present with the addition of VPA as compared to standard-of-care CRT. The second goal was to explore the associations between the proteomic alterations in response to VPA/RT/TMZ correlated to patient outcomes. The third goal was to use the proteomic profile to determine the mechanism of action of VPA in this setting. Materials and Methods: Serum obtained pre- and post-CRT was analyzed using an aptamer-based SOMAScan® proteomic assay. Twenty-nine patients received CRT plus VPA, and 53 patients received CRT alone. Clinical data were obtained via a database and chart review. Tests for differences in protein expression changes between radiation therapy (RT) with or without VPA were conducted for individual proteins using two-sided t-tests, considering p-values of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHumansTemozolomideValproic AcidHistone Deacetylase InhibitorsRetrospective StudiesProteomeProteomicsAntineoplastic Agents, AlkylatingHedgehog Proteins

Stichwörter der Autor:innen

HDAC inhibitorgliomaproteomicradiationvalproic acid

Substanzen

TemozolomideValproic AcidHistone Deacetylase InhibitorsProteomeAntineoplastic Agents, AlkylatingHedgehog Proteins

Autor:innen und Institutionen

  • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), 9000 Rockville Pike, Building 10, CRC, Bethesda, MD 20892, USA.
  • Computational and Systems Biology Branch, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, USA.

ORCID-Profile: Andra V Krauze, Erdal Tasci

Förderung

  • Intramural NIH HHS
  • NCI NIH intramural program

Zitieren

APA

Krauze, A. V., Zhao, Y., Li, M. C., Shih, J., Jiang, W., Tasci, E., Cooley Zgela, T., Sproull, M., Mackey, M., Shankavaram, U., Tofilon, P., & Camphausen, K. (2023). Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation. Biomolecules, 13(10), 1499. https://doi.org/10.3390/biom13101499

Vancouver

Krauze AV, Zhao Y, Li MC, Shih J, Jiang W, Tasci E, et al. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation. Biomolecules. 2023;13(10):1499. doi:10.3390/biom13101499

BibTeX
@article{Krauze2023,
  author = {Krauze, Andra V and Zhao, Yingdong and Li, Ming-Chung and Shih, Joanna and Jiang, Will and Tasci, Erdal and Cooley Zgela, Theresa and Sproull, Mary and Mackey, Megan and Shankavaram, Uma and Tofilon, Philip and Camphausen, Kevin},
  title = {Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma—Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {10},
  pages = {1499},
  doi = {10.3390/biom13101499}
}
Kostenlos starten →